Aberdeen Group plc Trims Stock Holdings in Krystal Biotech, Inc. $KRYS

Key Points

• Aberdeen Group plc has reduced its stake in Krystal Biotech, Inc. by 34.6%, now owning approximately 0.13% of the company worth $6.7 million.
• Other institutional investors have increased their holdings, with Fifth Third Bancorp boosting shares by 159.1% in the same quarter.
• Krystal Biotech reported an earnings per share of $1.29, surpassing expectations, and has seen various analysts adjust their price targets, with a consensus target of $210.75.

Aberdeen Group plc decreased its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 34.6% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 37,301 shares of the company's stock after selling 19,732 shares during the period. Aberdeen Group plc owned 0.13% of Krystal Biotech worth $6,725,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in KRYS. Hood River Capital Management LLC lifted its position in shares of Krystal Biotech by 2.1% in the fourth quarter. Hood River Capital Management LLC now owns 512,726 shares of the company's stock worth $80,324,000 after buying an additional 10,622 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Krystal Biotech by 16.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock worth $79,812,000 after acquiring an additional 71,200 shares during the last quarter. Soleus Capital Management L.P. boosted its position in shares of Krystal Biotech by 65.2% during the 4th quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company's stock valued at $56,144,000 after acquiring an additional 141,400 shares during the last quarter. Northern Trust Corp boosted its position in shares of Krystal Biotech by 9.9% during the 4th quarter. Northern Trust Corp now owns 262,263 shares of the company's stock valued at $41,086,000 after acquiring an additional 23,572 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Krystal Biotech by 3.0% in the first quarter. Charles Schwab Investment Management Inc. now owns 250,514 shares of the company's stock valued at $45,168,000 after purchasing an additional 7,344 shares in the last quarter. Institutional investors own 86.29% of the company's stock.

Krystal Biotech Stock Performance

KRYS stock traded up $0.11 during midday trading on Tuesday, reaching $146.88. 278,094 shares of the company traded hands, compared to its average volume of 417,806. The business has a 50 day moving average of $144.84 and a 200-day moving average of $154.39. Krystal Biotech, Inc. has a 52-week low of $122.80 and a 52-week high of $207.84. The firm has a market capitalization of $4.25 billion, a price-to-earnings ratio of 29.85 and a beta of 0.70.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.21. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%.The firm had revenue of $96.04 million for the quarter, compared to the consensus estimate of $95.42 million. Research analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 1,389 shares of the stock in a transaction that occurred on Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total value of $208,350.00. Following the sale, the insider directly owned 1,508,056 shares in the company, valued at approximately $226,208,400. This represents a 0.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold 49,800 shares of company stock valued at $7,487,943 in the last quarter. Corporate insiders own 13.70% of the company's stock.

Analyst Upgrades and Downgrades

KRYS has been the topic of several research reports. Citigroup restated a "neutral" rating and issued a $166.00 price target (down previously from $176.00) on shares of Krystal Biotech in a research report on Tuesday, August 5th. Bank of America reduced their price target on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a research report on Tuesday, July 22nd. Guggenheim reduced their price target on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Chardan Capital reduced their price target on shares of Krystal Biotech from $219.00 to $216.00 and set a "buy" rating on the stock in a research report on Friday. Finally, HC Wainwright restated a "buy" rating and set a $240.00 price objective on shares of Krystal Biotech in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $210.38.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).